Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

FDA Pulls Luveris NDA at Company’s Request

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

The FDA has withdrawn the NDA for injectable fertility drug Luveris at the request of the manufacturer. Source: Drug Industry Daily

Continue ReadingFDA Pulls Luveris NDA at Company’s Request

KaloBios Announces New Transparency Measures for Drug Prices

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

Although it has no drugs on the market, KaloBios Pharmaceuticals has announced that it will limit price increases to the rate of inflation or Consumer Price Index, and will do…

Continue ReadingKaloBios Announces New Transparency Measures for Drug Prices

AbbVie, Genentech Scoop Up FDA Approval for Leukemia Drug Venclexta

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

The FDA has given the green light to the chronic lymphocytic leukemia treatment Venclexta, which will be marketed by AbbVie and Roche’s Genentech unit. Source: Drug Industry Daily

Continue ReadingAbbVie, Genentech Scoop Up FDA Approval for Leukemia Drug Venclexta

Senate Committee Eyes Contempt Proceedings Against Valeant’s Pearson

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

Two lawmakers are mulling contempt proceedings against outgoing Valeant CEO J. Michael Pearson after he failed to provide a deposition on Friday as part of an investigation into drug pricing.…

Continue ReadingSenate Committee Eyes Contempt Proceedings Against Valeant’s Pearson

FDA: Consider Real-World Usage Early On To Avoid Medication Errors

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug Industry Daily

The FDA is pressing drugmakers to build risk assessments into their drug designs early on to cut down on medication errors. Source: Drug Industry Daily

Continue ReadingFDA: Consider Real-World Usage Early On To Avoid Medication Errors

Schnedar Steps Down From Role in OC, Cosgrove Takes Her Place

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

Cynthia Schnedar, director of CDER’s Office of Compliance, stepped down from her role on March 18 to take an unspecified private sector job, according to an email from CDER Director…

Continue ReadingSchnedar Steps Down From Role in OC, Cosgrove Takes Her Place

MHRA Slams Two Indian Drugmakers Over Purported GMP Deficiencies

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

British inspectors turned up a laundry list of apparent violations at two Indian manufacturers, leading them to block drugs from one of them and impose restrictions on the other’s GMP…

Continue ReadingMHRA Slams Two Indian Drugmakers Over Purported GMP Deficiencies

French Regulator Shutters Vaccine Manufacturer Over GMP Deficiencies

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

France’s National Agency for Medicines and Health Products Safety has ordered French vaccine maker Theravectys to halt production at its Villejuif plant for seven months after apparently finding numerous GMP…

Continue ReadingFrench Regulator Shutters Vaccine Manufacturer Over GMP Deficiencies

WHO Letter Blasts Cadila on Data Integrity Concerns and GMP Issues

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

Shortly after receiving an FDA warning letter for alleged major quality deficiencies, an Indian vaccine maker was slammed for data integrity issues and GMP violations by the World Health Organization.…

Continue ReadingWHO Letter Blasts Cadila on Data Integrity Concerns and GMP Issues

FDA Bashes Two Indian Drugmakers for Allegedly Flouting Procedures

  • Post author:Sam
  • Post published:April 11, 2016
  • Post category:Drug GMP Report

The FDA has slammed two Indian drugmakers — Emcure Pharmaceuticals and Lupin —for purported GMP violations. Source: Drug GMP Report

Continue ReadingFDA Bashes Two Indian Drugmakers for Allegedly Flouting Procedures
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company